K2 HealthVentures Equity Trust LLC 13D and 13G filings for TScan Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 4:05 pm Purchase | 2024-09-30 | 13G | TScan Therapeutics, Inc. TCRX | K2 HealthVentures Equity Trust LLC | 5,324,144 9.985% | 736,110 (+16.04%) | Filing |
| 2024-02-14 4:45 pm Purchase | 2023-12-31 | 13G | TScan Therapeutics, Inc. TCRX | K2 HealthVentures Equity Trust LLC | 4,588,034 9.985% | 2,488,225 (+118.50%) | Filing |
| 2022-09-30 5:21 pm Purchase | 2022-09-09 | 13G | TScan Therapeutics, Inc. TCRX | K2 HealthVentures Equity Trust LLC | 2,099,809 9.985% | 2,099,809 (New Position) | Filing |